![](https://pharmatimes.com/wp-content/uploads/2023/12/alzheimers.jpg)
LucyTx announces additional $12.5m research funding for neurological diseases
Alzheimer’s and Parkinson’s disease are responsible for more than 30 million cases globally Lucy Therapeutics (LucyTx) has announced it has raised $12.5m in additional funding to develop potentially new drugs and advance the company’s research programmes …